Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

Completed · Early Phase 1

Conditions studied: Neuroendocrine Tumors

In brief

The goal of this exploratory study is to test whether \[18F\]3F-PHPG can be used reliably to map the locations of tumors in patients with neuroendocrine tumors. If so, the results of this study will be used to support further development of \[18F\]3F-PHPG as a clinical tool for neuroendocrine tumor localization and staging.

Key facts

Study ID

NCT04510311

Run by

University of Michigan Rogel Cancer Center

People needed

32

Starts

2020-10-19

Expected to finish

2024-12-31

Last updated by the study team

2026-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Current neuroendocrine tumor diagnosis
• Able to lie flat for 60 minutes
• Provision of informed consent

You may not qualify if…

• Pregnancy or lactation
• Claustrophobia
• Inability to lie flat for 60 minutes
• Currently taking medications that may alter PET scans of neuroendocrine tumors with these tracers, including any of the following:
• Tricyclic antidepressants, which inhibit the norepinephrine transporter: desipramine, amitriptyline, imipramine
• Cold medications containing the sympathomimetic amines: phenylephrine, phenylpropanolamine, pseudoephedrine
• Nasal decongestants (some use phenylephrine as the active agent)
• Cocaine (which inhibits the norepinephrine transporter)
• Tetrabenazine (Xenazine), which inhibits the VMAT2 transporter
• Monoamine oxidase inhibitors (MAOI)
• Some antihypertensive drugs: reserpine, labetalol, α-methyldopa, clonidine

Where it is running

• University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.